REBLOZYL
Biological
Celgene Corporation
Total Payments
$13.2M
Transactions
54,615
Doctors
10,768
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.2M | 19,154 | 6,377 |
| 2023 | $2.7M | 17,775 | 6,058 |
| 2022 | $2.6M | 12,411 | 4,869 |
| 2021 | $2.6M | 3,496 | 1,858 |
| 2020 | $2.1M | 1,779 | 930 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.5M | 404 | 56.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.3M | 1,141 | 25.0% |
| Food and Beverage | $1.3M | 51,571 | 9.7% |
| Consulting Fee | $446,939 | 260 | 3.4% |
| Travel and Lodging | $443,987 | 1,023 | 3.4% |
| Space rental or facility fees (teaching hospital only) | $182,330 | 65 | 1.4% |
| Education | $46,066 | 147 | 0.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,000 | 2 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,351 | 2 | 0.0% |
Payments by Type
Research
$7.5M
404 transactions
General
$5.7M
54,211 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Open-label, Randomized Study to compare | Celgene Corporation | $595,304 | 0 |
| Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (ACE-536) initiated at maximum approved dose in LR-MDS | E.R. Squibb & Sons, L.L.C. | $489,256 | 0 |
| Ph III Reblozyl B-Thal TDT vs BSC (THAL-001) | Celgene Corporation | $487,287 | 0 |
| Ph III Reblozyl vs Epoetin alpha MDS 1L (COMMANDS) | Celgene Corporation | $375,300 | 0 |
| Ph III Reblozyl MDS NTD 1L | E.R. Squibb & Sons, L.L.C. | $362,939 | 0 |
| A Phase 3b, open label, single-arm rollover study | Celgene Corporation | $357,754 | 0 |
| Celgene Connect Myeloid Disease Registry | Celgene Corporation | $314,641 | 0 |
| Ph III Reblozyl vs Pbo Myelofibrosis (INDEPENDENCE) | Celgene Corporation | $312,327 | 0 |
| A Phase 3, Open-label, Randomized Study to compare - A Phase 3, Open-label, Randomized Study to compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin alpha for the treatment of Anemia due to IPSS-R very low, Low or Intermediate Risk due | Celgene Corporation | $312,300 | 0 |
| A Phase-2 Study To Determine Efficacy and Safety o | Celgene Corporation | $305,256 | 0 |
| A Phase 3b, open label, single-arm rollover study - A Phase 3b, open label, single-arm rollover study to evaluate long term safety in subjects who have participated in other Luspatercept (Ace-536) clinical trials. | Celgene Corporation | $256,393 | 0 |
| A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions | Celgene Corporation | $252,036 | 0 |
| A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blo | E.R. Squibb & Sons, L.L.C. | $238,975 | 0 |
| A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence | Celgene Corporation | $234,476 | 0 |
| Ph II Reblozyl B-Thal vs. BSC NTDT | Celgene Corporation | $224,019 | 0 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | Celgene Corporation | $218,200 | 0 |
| A Phase 3, double-blind, randomized study to compa | Celgene Corporation | $215,362 | 0 |
| A Phase 3, Double-Blind, Placebo Controlled Multic | Celgene Corporation | $212,493 | 0 |
| A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia | Celgene Corporation | $193,706 | 0 |
| A Phase 3, Double-blind, Randomized Study to Compa | Celgene Corporation | $189,608 | 0 |
Top Doctors Receiving Payments for REBLOZYL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Irene Hutchins | — | La Quinta, CA | $7.7M | 532 |
| , MD, MA | Medical Oncology | Durham, NC | $270,176 | 228 |
| , M.D | Hematology | Hackensack, NJ | $219,703 | 173 |
| , M.D | Specialist | Atlanta, GA | $185,960 | 112 |
| , M.D | Hematology | Hackensack, NJ | $179,700 | 107 |
| , MD | Medical Oncology | Dallas, TX | $168,359 | 143 |
| Bart Scott | Medical Oncology | Seattle, WA | $133,965 | 88 |
| George Yaghmour | Hematology & Oncology | Los Angeles, CA | $127,082 | 86 |
| , M.D | Hematology & Oncology | Houston, TX | $117,179 | 121 |
| , MD | Medical Oncology | Phoenix, AZ | $108,596 | 128 |
| , M.D | Internal Medicine | Loma Linda, CA | $101,960 | 54 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $101,347 | 79 |
| , MD | Internal Medicine | Stony Brook, NY | $91,502 | 66 |
| , MD | Hematology & Oncology | Nashville, TN | $83,159 | 65 |
| , M.D | Specialist | Columbia, MD | $77,963 | 58 |
| , M.D | Hematology | Orange City, FL | $75,677 | 78 |
| , M.D | Hematology & Oncology | Somerset, KY | $75,288 | 63 |
| , M.D | Hematology & Oncology | Wexford, PA | $70,938 | 41 |
| , M.D | Specialist | Sacramento, CA | $67,379 | 37 |
| Michael Bishop | Hematology & Oncology | New Lenox, IL | $63,384 | 35 |
| , MD | Hematology | Coeur D Alene, ID | $58,361 | 64 |
| , M.D | Medical Oncology | Bethesda, MD | $56,082 | 30 |
| , MD | Hematology & Oncology | San Diego, CA | $53,967 | 38 |
| , M.D | Internal Medicine | Terre Haute, IN | $48,615 | 58 |
| , M.D | Hematology | Tampa, FL | $44,579 | 26 |
Ad
Manufacturing Companies
- Celgene Corporation $8.5M
- E.R. Squibb & Sons, L.L.C. $4.7M
- Merck Sharp & Dohme LLC $23,308
Product Information
- Type Biological
- Total Payments $13.2M
- Total Doctors 10,768
- Transactions 54,615
About REBLOZYL
REBLOZYL is a biological associated with $13.2M in payments to 10,768 healthcare providers, recorded across 54,615 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2020 to 2024. In 2024, $3.2M was paid across 19,154 transactions to 6,377 doctors.
The most common payment nature for REBLOZYL is "Unspecified" ($7.5M, 56.8% of total).
REBLOZYL is associated with 20 research studies, including "A Phase 3, Open-label, Randomized Study to compare" ($595,304).